Walvax’s PCV13 Officially Exported to India
(November 27, 2024, Kunming) Walvax Biotechnology Co., Ltd. ("Walvax", together with its subsidiaries, the "Group", stock code: 300142.SZ) is pleased to announce that the Group’s subsidiary, Yuxi Walvax Biotechnology Co., Ltd., has officially exported its 13-valent Pneumococcal Conjugate Vaccine ("PCV13") to India for the first time.
In June 2024, the Drugs Controller General of India (DCGI) granted Walvax the Marketing Authorization for its PCV13. This product will provide effective protection for Indian children against invasive diseases caused by 13 serotypes of Streptococcus pneumoniae.
With the addition of India, the number of export countries for PCV13 has increased to six. Previously, it has been exported to Morocco, Bangladesh, Thailand, Indonesia, and the Philippines. As the world's most populous country, India has 23 million newborns each year, which is of great strategic significance to Walvax. This export marks the Company's further expansion in the South Asian market.
About Walvax
Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines. Headquartered in China's southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 (300142.SZ) and started business expansion from conventional vaccines to innovative vaccines. Walvax's purpose is to help everyone live a healthy life and has delivered vaccine products to 22 countries. For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.